🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

635 results for “dose” Clear

  1. A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 120-hour continuous infusion at two dose levels versus placebo in healthy subjects

    Lacuna Pharma Pty Ltd

    Sepsis and Septic Shock

    phase 1 other active

    1 trial

  2. A randomized, single-center, double-blind, placebo-controlled, first-in-human trial with single and multiple ascending doses to determine safety, tolerability, and pharmacokinetics of GRT7040 in healthy volunteers

    Gruenenthal GmbH

    Treatment of pain

    phase 1 other active

    1 trial

  3. A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity

    NovoThirteen

    Type 2 diabetes mellitus

    phase 1 other active

    1 trial

  4. A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A

    NovoThirteen

    Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity.

    phase 1 other active

    1 trial

  5. A research study looking at how different doses of study medicine (Inno8) works in the body of healthy men.

    NovoThirteen

    Prophylaxis and on-demand treatment respectively in patients with haemophilia A with or without FVIII inhibitors.

    phase 1 other active

    1 trial

  6. A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity

    NovoThirteen

    obesity

    phase 1 other active

    1 trial

  7. A research study to evaluate the effects of single doses of NNC0614-0001 in healthy adult volunteers, and participants with hereditary haemochromatosis type 1.

    NovoThirteen

    Hereditary haemochromatosis (HH) type 1

    phase 1 other active

    1 trial

  8. A single and multiple ascending dose study of topical ladarixin ophthalmic solution in healthy volunteers

    Dompe' Farmaceutici S.p.A.

    Ocular inflammatory conditions

    phase 1 other active

    1 trial

  9. A single dose, randomized, double-blind 2-arm parallel-group study to compare the pharmacokinetics, immunogenicity, and safety for PB016 versus US-licensed Entyvio® after subcutaneous administration in healthy participants

    Lacuna Pharma Pty Ltd

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  10. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infection

    phase 1 other active

    1 trial

  11. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated tablets (Polfa Tarchomin S.A., Poland) versus Froxiga 10 mg film-coated tablets (AstraZeneca AB, Sweden) in healthy volunteers under fasting conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    intended for treatment of for the treatment of (2): • insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. • symptomatic chronic heart failure. • chronic kidney disease.

    phase 1 other active

    1 trial

  12. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Taromentin® 500 mg + 125 mg film-coated tablets versus Augmentin® 500 mg + 125 mg film-coated tablets in healthy volunteers under fed conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infections

    phase 1 other active

    1 trial

  13. A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid film-coated tablet formulations in healthy volunteers under fed conditions.

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infections

    phase 1 other active

    1 trial

  14. A single-dose, randomized, two-period, two-sequence, crossover comparative bioavailability study on formulations containing ramipril, amlodipine and indapamide in combination product versus Triatec® 10 mg capsules (Sanofi - Produtos Farmacêuticos, Lda., Portugal), containing ramipril, Norvasc® 10 mg, tablets (Upjohn EESV, the Netherlands), containing amlodipine and Natrilix® 2.5 mg film-coated tablets (Les Laboratoires Servier, France), containing indapamide co-administered together as reference in healthy

    Lacuna Pharma Pty Ltd

    hypertension

    phase 1 other active

    1 trial

  15. A single-dose, randomized, two-period, two-sequence, crossover pilot bioequivalence study on formulations containing rivaroxaban and acetylsalicylic acid in healthy volunteers under fasting conditions.

    s.r.o.

    increased blood clotting

    phase 1 other active

    1 trial

  16. A study in healthy men to find out how different doses of BI 3009947 are tolerated and how different formulations or food influence how BI 3009947 is taken up into the blood

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  17. A study in healthy men to test how different doses of BI 3031185 are tolerated and how food influences the amount of BI 3031185 in the blood

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  18. A study in healthy men to test how well different doses of BI 3731579 are tolerated

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  19. A study in healthy men to test how well different doses of BI 3776528 are tolerated

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  20. A study in healthy men to test how well different doses of BI 3821001 are tolerated

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  21. A study in healthy people to compare how 2 different high dose formulations of BI 1015550 are taken up in the body

    Boehringer Ingelheim

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  22. A study in healthy people to compare how 2 different low dose formulations of BI 1015550 are taken up in the body

    Boehringer Ingelheim

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  23. A study in healthy people to test how 2 different doses of BI 1291583 are taken up in the body when given in 3 different formulations.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  24. A study in healthy people to test how well different doses of BI 3000202 are tolerated and how they affect the way the body handles midazolam

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources